Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial

European Respiratory Journal

Volumn 19, Issue 5, 2002, Pages 936-943

  Aalbers, R ^a   Ayres, J ^a   Backer, V ^a   Decramer, M ^a   Lier, P A ^a   Magyar, P ^a   Malolepszy, J ^a   Ruffin, R ^a   Sybrecht, G W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Bronchodilation; Chronic obstructive pulmonary disease; Formoterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; FORMOTEROL; GLUCOCORTICOID; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; TERBUTALINE; TERBUTALINE SULFATE; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SPIROMETRY; SYMPTOM; TREATMENT OUTCOME; VITAL CAPACITY; WALKING; EXERCISE TEST; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RESPIRATORY TRACT EXAMINATION; TIME;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; DOUBLE-BLIND METHOD; ETHANOLAMINES; EXERCISE TEST; FEMALE; HUMAN; MALE; MIDDLE AGE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0036014549     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00240902     Document Type: Article

References (24)

1. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force
2. The impact of COPD on lung health worldwide: Epidemiology and incidence
3. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
4. BTS guidelines for the management of chronic obstructive pulmonary disease
5. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life
6. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease
7. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma
8. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis
9. Lung volumes and forced ventilatory flows
10. Development of a shuttle walking test of disability in patients with chronic airways obstruction
11. Psychophysical bases of perceived exertion
12. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
13. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction
14. The effect of inhaled terbutaline on FEV1, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease
15. A short outpatient pulmonary rehabilitation programme: Immediate and longer-term effects on exercise performance and quality of life
16. Effect of nutritional status on exercise performance in patients with chronic obstructive pulmonary disease
17. The endurance shuttle walk: A new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease
18. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease
19. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
20. Assessment of bronchodilator efficacy in symptomatic COPD: Is spirometry useful?
21. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease
22. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in Chronic Obstructive Pulmonary Disease
23. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease
24. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease